Chu Choi Ying, Huang Junjie, Liew Jamie Jie Mei, Sawhney Apurva, Liu Xianjing, Zhong Chaoying, Lin Jianli, Hang Junjie, Zhong Claire Chenwen, Yuan Jinqiu, Wong Martin C S
The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Centre for Health Education and Health Promotion, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Cancer Rep (Hoboken). 2025 Apr;8(4):e70140. doi: 10.1002/cnr2.70140.
Colorectal cancer (CRC) screening, effective for early detection of CRC, was recently implemented by the Hong Kong government using the quantitative Fecal Immunochemical Test (FIT). However, consistently low participation rates and heavy reliance on colonoscopy for CRC screening has created a substantial burden on the healthcare system.
This study examined the feasibility, acceptability, and satisfaction of utilizing the novel non-invasive biomarker test Colotect for early detection of CRC.
In-depth, qualitative telephone interviews were conducted with 16 participants (≥ 50 years old) who were eligible for the government CRC screening program. Participants were recruited via community health centres in Hong Kong between July and August 2022. The Consolidated Framework for Implementation Research (CFIR) was used to prepare the interview guide exploring the perceptions, attitudes, and barriers to using Colotect. The data collected was categorized into eight themes corresponding to the CFIR interventional characteristics domain, including intervention sources, evidence strength & quality, relative advantage, adaptability, complexity, design quality and packaging, and cost.
Overall, participants reflected positive attitudes and perceptions toward Colotect use, along with identifying difficulties associated with its use. Modifications to test kits were proposed corresponding to the issues identified. In summary, this study demonstrated the feasibility and acceptability of using Colotect in CRC screening program. Future studies should examine the applicability, acceptability, efficiency, and cost-effectiveness of the test in real-world settings.
香港政府最近采用定量粪便免疫化学检测(FIT)实施了对结直肠癌(CRC)进行早期检测的有效筛查。然而,参与率持续较低以及在CRC筛查中严重依赖结肠镜检查给医疗系统带来了沉重负担。
本研究探讨了利用新型非侵入性生物标志物检测Colotect进行CRC早期检测的可行性、可接受性和满意度。
对16名符合政府CRC筛查计划资格的参与者(≥50岁)进行了深入的定性电话访谈。参与者于2022年7月至8月期间通过香港的社区健康中心招募。采用实施研究综合框架(CFIR)编写访谈指南,以探讨使用Colotect的认知、态度和障碍。收集的数据被归类为与CFIR干预特征领域相对应的八个主题,包括干预来源、证据强度与质量、相对优势、适应性、复杂性、设计质量与包装以及成本。
总体而言,参与者对使用Colotect持积极态度和看法,同时也指出了使用过程中存在的困难。针对所发现的问题提出了对检测试剂盒的改进建议。总之,本研究证明了在CRC筛查计划中使用Colotect的可行性和可接受性。未来的研究应考察该检测在实际环境中的适用性、可接受性、效率和成本效益。